Analysis of 1,862 samples of major cancer types including sarcomas, colon, breast, and lung carcinomas and gastrointestinal stromal tumors, showed MED12 mutations exclusively in 52.2% (35/67) of uterine leiomyomas except for 0.3% (1/389) of colon carcinomas [16]. This evidence concerns the gene MED12 and Uterine leiomyoma.